Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Genelux CorporationNASDAQ: GNLX

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$5K, compared with $29K a year earlier. Over 3 fiscal years it compounded at +65.1% a year.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -117.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5K-155.6% QoQ
Last fiscal yearDec 2025
$9K-85.9% YoY
Year agoMar 2025
$29K-117.2% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-117.2%——
1 year-85.9%——
3-year CAGR+65.1%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
9K USD
Year-over-year change
-85.9%
4-year CAGR
+45.6%

Accumulated OCI vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -117.2% is the 6th highest of 9, against a peer median of -102.8%.
  • Accumulated OCI amounts to 0.0% of total assets for GNLX, versus a peer median of 0.0%.
GNLX Competitors
Accumulated OCI for GNLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACIUAC Immune S.A.Mar 2026CHF 7K CHF+800.0%-11.2%0.0%
DRTSAlpha Tau Medical Ltd.Mar 2026$0 USD——0.0%
CADLCandel Therapeutics, Inc.Mar 2026$0 USD——0.0%
ALDXAldeyra Therapeutics, Inc.Mar 2026$0 USD-100.0%—0.0%
GNLXGenelux CorporationMar 2026-$5K USD-117.2%+65.1%0.0%
LYELLyell Immunopharma, Inc.Mar 2026-$9K USD-105.7%—0.0%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026-$142K USD-163.0%—0.1%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026-$253K USD-248.8%—0.1%
SLNSilence Therapeutics plcMar 2026-$3.37M USD-141.7%—2.9%
MREOMereo BioPharma Group plcMar 2026-$12.57M USD+17.8%—31.0%
CLLSCellectis S.A.Mar 2026-$33.2M USD+10.9%—11.5%
Peer median (excluding GNLX) —-102.8%-11.2%0.0%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.5M397K9.42M8.57M5.33M
Short-term Investments0013.77M22.33M9.26M
Net Receivables00000
Inventory00000
Other Current Assets1.33M1.5M1.01M653K535K
Total Current Assets5.82M1.89M24.2M31.55M15.13M
Property, Plant & Equipment (Net)2.21M1.98M3.6M3.08M3.75M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets92K1.66M92K92K144K
Total Non-current Assets2.3M3.64M3.69M3.17M3.9M
Total Assets8.13M5.53M27.89M34.72M19.03M
Account Payables4.46M6.78M3.78M5.57M4.36M
Short-term Debt6.16M16.4M653K329K0
Tax Payables00000
Deferred Revenue4.5M170K000
Other Current Liabilities4.11M5.16M000
Total Current Liabilities22.48M31.63M6.55M6.9M6.23M
Long-term Debt18.02M8.52M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities18.75M9.69M1.87M1.54M1.26M
Total Liabilities41.24M41.31M8.42M8.44M7.48M
Common Stock9K9K27K35K38K
Retained Earnings(184.58M)(189.78M)(221.52M)(251.39M)(283.54M)
Accumulated OCI2K2K14K64K9K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(33.11M)(35.78M)19.47M26.27M11.54M
Total Debt25.31M26.35M2.52M1.87M1.69M
Net Debt20.82M25.96M(6.9M)(6.7M)(3.65M)

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.